Haemokinesis’ Post

Our Camstent Bacteria-Phobic coated urethral catheters are proven to exhibit enhanced resistance to fibrinogen depositation, biofilm formation and encrustation, reducing the risks associated with catheter associated urinary tract infection and encrustation. Read the clinical paper here https://lnkd.in/eKDmqgKD #catheter #continence #bladderandbowel #UTI #urology

Did you miss last week's webinar on 'Drug consumption rooms in Europe — current practices and future scenarios'? You can now watch the recording 📽️ https://lnkd.in/dFpXCqyg #HarmReduction #DrugConsumptionRooms

Novel excipients are a critical component to developing new drug modalities and therapies that can help improve patient health outcomes, but the limited availability of these excipients creates barriers to drug development and innovation. We believe that policies and initiatives designed to promote the introduction and use of novel excipients should employ both increased stakeholder cooperation and coordination and regulatory development. Learn more about the importance of addressing and reducing barriers to novel excipients and our policy positions at our Novel Excipients Knowledge Hub ➡️: https://ow.ly/s77N50TQVUP

I've been impressed by how John F. Crowley, new CEO of the Biotechnology Innovation Organization, has hit the ground running in his first 90 days, even as he had to address a crisis within his first 3 days(!) when BIO received a letter from Congress related to the BIosecure Act. As the outstanding biotech CEO he is, John has already updated BIO's key priorities and goals, reorganized and refocused the organization to concentrate force on achieving those goals, and repositioned BIO to give it an even more effective voice at the table regarding US policy related to #biotech #innovation and #security. His initiatives have been fully supported by BIO's Executive Committee and Board. John is positioning BIO to reflect the fact that #biotechnology is one of the US' most important strategic assets, and that the country must treat it as such. In this era of astonishing advances in our ability to intervene at the level of the genome, we must recognize that—as with the splitting of the atom—there is potential for enormous good, but also for almost unimaginable evil. A strong BIO will play key roles in helping us to navigate both the opportunities and threats.

SDBN Feed: With Latest Expansion in Ohio, Resilience Can Best Serve Partners and Patients https://lnkd.in/ggd9n2-U Pictured: The Resilience Cincinnati facility, which handles fill/finish and device assembly and packaging/Resilience Expecting the recent increase in drug product demand to continue, Resilience is taking steps to meet that demand and fulfill patient needs, [...]

In this executive summary, Catalent expert Nicole Gray shares her experience of decentralized trials, highlighting how clinical supply can be scaled up as trial phases progress, and technological solutions for accelerated trial deployment. https://ow.ly/OIWw50U0SIn

I fully agree. Treatments like abaloparatide offer a massive opportunity for patients but present a major challenge to healthcare providers - how do we find these "very high risk" patients? The comment in the article about poor Fracture Liaison Service provision already concedes that the patient must fracture first before being prescribed treatment. Not only are we waiting for failure but failing to act when it occurs. Sarah Jarvis, MBE, an ambassador for the ROS made a similar point which I will paste a link to below. Better case finding is the answer in my view and ideally before the patient fractures. I have to declare a strong bias here but radiology is the ideal touch point to identify very high risk patients both pre and post fracture. We will be publishing our analysis of the impact of opportunistic screening from wrist X-rays very soon.

POST BUDGET REACTIONS: MTaI (Medical Technology Association of India) believes that the Union Budget 2024 is a pragmatic one. The leading association of global medical technology companies has welcomed the reduction of custom duties on specific categories of #medicaldevices Click to read: https://lnkd.in/g7PQ8csf PAVAN CHOUDARY #Budget2024withBioVoiceNews #medtech #medicaltechnology #healthtech #budget2024 #biovoicenews

An insightful panel discussion - well worth watching to hear how different regulatory, patient group and pharma stakeholders incorporate the patient perspective to help ensure approved therapies are fit for purpose

FDA is considering redesigning its device and diagnostics premarket review process to improve expectations, ensure better first-time submissions, and allow more flexibility in the review process, according to Jeff Shuren, director of the Center for Devices and Radiological Health. The objective would be to reduce the number of deficiency letters and complete more reviews in a single cycle. Ferdous Al-Faruque reports in Regulatory Focus 🖊️✅ https://bit.ly/444CVC0